Evaluation of Neuroprotective Effects of Sugammadex Following a Head Trauma in an Experimental Study

J Craniofac Surg. 2022 Jun 1;33(4):1260-1264. doi: 10.1097/SCS.0000000000008292. Epub 2021 Oct 22.

Abstract

To compare the efficacy of mannitol, the first choice of treatment in daily clinical practice for head trauma, and sugammadex, a frequently used neuroanesthesia in recent years. A total of 35 male rats were randomly selected and were divided into 5 groups, each comprising 7 rats. The groups were divided into Group I, sham (n = 7); Group II, control (head trauma, n = 7); Group III, treated with mannitol (head trauma, mannitol 20% 1 g/kg, n = 7); Group IV, treated with sugammadex (head trauma, sugammadex 100 mg/ kg, n = 7); and Group V, treated with mannitol and sugammadex (head trauma, mannitol 20% 1 g/kg and sugammadex 100 mg/kg, n = 7). After the sacrification, histological examination and immu-nohistochemical staining were performed in the brain of all subjects. Mann-Whitney U test was used to evaluate the significance between neuronal density, neuronal nuclei, and activated caspase-3 immunohistochemistry results measured from the prefrontal cortex. Neuronal density showing neuronal viability was observed to significantly increase in Group III compared to Group IV. However, neuronal nuclei immunohistochemistry showing apoptotic neurons also significantly increased. The present study has shown that sugammadex, an agent reversing the effects of neuromuscular blocking agents, has neuroprotective effects and is as effective as mannitol.

MeSH terms

  • Animals
  • Brain / pathology
  • Craniocerebral Trauma* / drug therapy
  • Humans
  • Male
  • Mannitol / pharmacology
  • Mannitol / therapeutic use
  • Neuroprotective Agents* / pharmacology
  • Neuroprotective Agents* / therapeutic use
  • Rats
  • Sugammadex / pharmacology

Substances

  • Neuroprotective Agents
  • Sugammadex
  • Mannitol